

Table 3 Association of mRNA- and protein-validated hub genes with overall survival and progression-free survival

	Hub genes	HR	Logrank P	Dataset	Samples
Overall survival (OS)	<i>CD74</i>	0.82 (0.71 - 0.96)	0.012	All	Serous ovarian carcinoma (n=1207)
	<i>SYK</i>	0.59 (0.41 - 0.86)	0.0053	GSE9891	Frozen tissue of ovary, Fallopian tube, or peritoneum carcinoma (n=285)
	<i>CD74</i>	0.66 (0.45 - 0.96)	0.028		
	<i>CD74</i>	0.41 (0.22 - 0.77)	0.0041	GSE18520	Advanced stage ovarian carcinoma (n=53)
Progression-free survival (PFS)	<i>SYK</i>	1.32 (1.12 - 1.56)	0.00084	All	Serous ovarian carcinoma (n=1104)
	<i>LCP1</i>	0.78 (0.62 - 0.98)	0.033	TCGA	OvCa (n=522)
	<i>SYK</i>	0.7 (0.52 - 0.93)	0.013	GSE9891	Frozen tissue of ovary, Fallopian tube, or peritoneum carcinoma (n=285)
	<i>SYK</i>	0.53 (0.3 - 0.93)	0.026	GSE30161	Treated OvCa patients with III-IV stages (n=54)
	<i>CD74</i>	1.99 (1.11 - 3.58)	0.02		
	<i>SYK</i>	0.09 (0.02 - 0.33)	6.50E-06	GSE51373	Including 12 chemoresistant and 16 sensitive chemotherapy HGSOCS (n=28)

HGSOC: high-grade ovarian serous carcinoma